Genome editing to model and reverse a prevalent ... - MPN Voice

MPN Voice

10,604 members14,656 posts

Genome editing to model and reverse a prevalent mutation associated with MPN

Manouche profile image
7 Replies

“Much work remains to be done regarding the safety of therapeutic gene editing, but there is accumulating evidence that causative mutations in monogenic hematopoietic disorders can be repaired in patient HSCs. Curing overtly oncogenic disorders using genome editing is difficult due to the need for complete allele conversion, since cells that escape the edit may eventually recover to take over the population. However, since the increased co-culture fitness of the JAK2 V617F mutation is a gradual event, it may be possible that even incomplete editing could lead to extended disease remission.”

journals.plos.org/plosone/a...

Written by
Manouche profile image
Manouche
To view profiles and participate in discussions please or .
7 Replies
MPort profile image
MPort

Thank you. These posts show scientific research that gives us hope.

Aldebaran25 profile image
Aldebaran25

Happy to see we are actively on the radar of CRISPR technology

EmeraldA profile image
EmeraldA

Thank you this has gave me some hope today!!

hunter5582 profile image
hunter5582

Very interesting. Perhaps someday a cure.

Aneliv9 profile image
Aneliv9

Does this only apply to Jak2 mutation?

Manouche profile image
Manouche in reply to Aneliv9

This study only applies to Jak2, but regarding MPN genome editing potentially applies to all monogenic mutation.

MPNBlog profile image
MPNBlog

Hi ManoucheThanks for this link. Ever since I was diagnosed (Feb 2017 PV) I have wondered if a CRISPER cure was a possibility. My initial question was 'Why can't we just reverse the valine substitution for phenylalanine that causes the V617F mutation in the JAK2 gene? Surely CRISPER can do that?' When I asked, my original haem mused that that should be theoretically possible, but it wasn't as simple as that and there were a lot of complications with CRISPER, and it was very expensive. eg One problem that has arisen since then is unwanted deletions. The 'competitive growth advantage provided by the mutation' noted in the article seems a problem too unless every single mutated cell can be deleted. However, this article gives some hope that at least CRISPER is being considered. Surely a single mutation disease is a good place to start? I would think that any cure was a long way off however as these studies are still at the mouse level. I'm not aware of these researchers, but they are from UCSF. Hopefully this won't just disappear as some other initial research work has done. There just aren't enough MPNers to instigate significant research to really make a difference, such as the volume of research done in breast cancer for example.

You may also like...

A model of good MPN care

Prevalence of the JAK2V617F Mutation in Patients with Ischemic Stroke

study reveals a JAK2V617F mutation prevalence (12.2%) in a stroke population that is substantially...

Whole-genome sequencing shows driver mutations can be acquired very early in life

com/medical-information/whole-genome-sequencing-shows-driver-mutations-can-be-acquired-very-early-in

JAK2  Reversible Activation Shows an Essential Requirement for Jak2V617F in MPN

achievable therapeutic doses, and we and others have elucidated mechanisms by which mutant JAK2 can...

Can we have the Pfizer vaccine

Plus suggestions those with immunosuppresion disorders may not be able to have it. Trying to be...